TGF-β-induced IOP elevations are mediated by RhoA in the early but not the late fibrotic phase of open angle glaucoma.
Hill LJ, Mead B, Thomas CN, Foale S, Feinstein E, Berry M, Blanch RJ, Ahmed Z,Logan A.
Mol Vis. 2018 Oct 29;24:712-726. eCollection 2018. PubMed PMID: 30429640; PubMed Central PMCID: PMC6205807.

Caspase-2 Mediates Site-Specific Retinal Ganglion Cell Death After Blunt Ocular Injury
Chloe N. Thomas; Adam M. Thompson; Eleanor McCance; Martin Berry; Ann Logan; Richard J. Blanch; Zubair Ahmed
Investigative Ophthalmology & Visual Science September 2018, Vol.59, 4453-4462. doi:10.1167/iovs.18-24045

Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury
Segav Demirjian, Gorav Ailawadi, Martin Polinsky, Dani Bitran, Shuli Silberman, Stanton Keith Shernan, Michel Burnier, Marta Hamilton, Elizabeth Squiers, Shai Erlich, Daniel Rothenstein, Samina Khan, and Lakhmir S. Chawla
Kidney International Reports. 2017;2(5):836-843. doi:10.1016/j.ekir.2017.03.016

Neuroprotective drug may be possible NAION therapy
Neil R. Miller, MD, NORDIC
Publication by Nordic

Corteville D, Still R, JayasankarV, Szabo G, Swaminathan M, Lamy A, Lehner L, Thielmann M, Brown C, Squiers EC, Schwertschlag U, Potts A, Patel A, Messersmith E, Odenheimer D, Rothenstein D, Erlich Sand the QRK209 Study Group.
Presentation at ASN, Kidney Week, 2017, High impact clinical trials session, Abstract: SA-OR124

Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury.
Demirjian S, Ailawadi G, Polinsky M, Bitran D, Silberman S, Shernan SK, Burnier M, Hamilton M, Squiers E, Erlich S, Rothenstein D, Khan S, Chawla LS.
Kidney Int Rep. 2017 Apr 25;2(5):836-843. doi: 10.1016/j.ekir.2017.03.016. eCollection 2017 Sep.

siRNA-Mediated Knockdown of the mTOR Inhibitor RTP801 Promotes Retinal Ganglion Cell Survival and Axon Elongation by Direct and Indirect Mechanisms.
Morgan-Warren PJ, O’Neill J, de Cogan F, Spivak I, Ashush H, Kalinski H, Ahmed Z, Berry M, Feinstein E, Scott RA, Logan A.
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):429-43. doi: 10.1167/iovs.15-17511.
Long-term neuroprotection of retinal ganglion cells by inhibiting caspase-2.
Vigneswara V, Ahmed Z.
Cell Death Discov. 2016 Jun 13;2:16044. doi: 10.1038/cddiscovery.2016.44. eCollection 2016.

Relationship Between Delayed Graft Function (DGF) Severity and Predicted DGF Risk
E. Squiers, B. Irish, D. Odenheimer, S. Erlich, J. Grinyo, S. Feng, On Behalf of Quark DGF Study Investigators.
Am J Transplant. 2015; 15 (suppl 3). Presented 2015 American Transplant Congress

REDD2-mediated inhibition of mTOR promotes dendrite retraction induced by axonal injury.
Morquette B, Morquette P, Agostinone J, Feinstein E, McKinney RA, Kolta A, Di Polo A.
Cell Death Differ. 2015 Apr;22(4):612-25. doi: 10.1038/cdd.2014.149. Epub 2014 Sep 26.

Treatment with QPI-1002, a Short Interfering (SI) RNA for the Prophylaxis of Delayed Graft Function.
V. Peddi, L. Ratner, M.Cooper, O. Gaber, S. Feng, P. Tso, V. Bowers, R. Naraghi, K. Budde,M. Polinsky, E. Squiers, S. Erlich,  Study Investigators Group.
Abstract# 2967, Late Breaking Oral Presentation, The World Transplant Congress 2014 Abstract Supplement jointly published by the American Journal of Transplantation and Transplantation on behalf of the American Society of Transplant Surgeons, The Transplantation Society and the American Society  of Transplantation.

Altered nutrient response of mTORC1 as a result of changes in REDD1 expression: effect of obesity vs. REDD1 deficiency.
Williamson DL, Li Z, Tuder RM, Feinstein E, Kimball SR, Dungan CM.
J Appl Physiol (1985). 2014 Aug 1;117(3):246-56. doi: 10.1152/japplphysiol.01350.2013. Epub 2014 May 29.

Sestrin2 inhibits uncoupling protein 1 expression through suppressing reactive oxygen species.
Ro SH, Nam M, Jang I, Park HW, Park H, Semple IA, Kim M, Kim JS, Park H, Einat P, Damari G, Golikov M, Feinstein E, Lee JH.
Proc Natl Acad Sci U S A. 2014 May 27;111(21):7849-54. doi: 10.1073/pnas.1401787111. Epub 2014 May 13.

Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection.
Solano EC, Kornbrust DJ, Beaudry A, Foy JW, Schneider DJ, Thompson JD.
Nucleic Acid Ther. 2014 Aug;24(4):258-66. doi: 10.1089/nat.2014.0489.

Combined suppression of CASP2 and CASP6 protects retinal ganglion cells from apoptosis and promotes axon regeneration through CNTF-mediated JAK/STAT signalling.
Vigneswara V, Akpan N, Berry M, Logan A, Troy CM, Ahmed Z.
Brain. 2014 Jun;137(Pt 6):1656-75. doi: 10.1093/brain/awu037. Epub 2014 Apr 10.

RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801.
Rittenhouse KD, Johnson TR, Vicini P, Hirakawa B, Kalabat D, Yang AH, Huang W, Basile AS.
Invest Ophthalmol Vis Sci. 2014 Mar 4;55(3):1232-40. doi: 10.1167/iovs.13-13449.

A Phase I Open Label, Dose Escalation Trial Of QPI-1007 Delivered By A Single Intravitreal (IVT) Injection To Subjects With Low Visual Acuity And Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Andrew Antoszyk; Bradley Katz; Rishi Singh; Rabia Gurses-Ozden; Shai Erlich; Daniel Rothenstein; Nir Sharon; Jennifer Hodge; Leonard Levin; Neil Miller; QPI-1007 NAION Study Group Consisting of Various Institutions in Israel and the United States
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4575. doi:

DDIT4/REDD1/RTP801 is a novel negative regulator of Schwann cell myelination.
Noseda R, Belin S, Piguet F, Vaccari I, Scarlino S, Brambilla P, Martinelli Boneschi F, Feltri ML, Wrabetz L, Quattrini A, Feinstein E, Huganir RL, Bolino A.
J Neurosci. 2013 Sep 18;33(38):15295-305. doi: 10.1523/JNEUROSCI.2408-13.2013.

siRNA targeting Hes5 augments hair cell regeneration in aminoglycoside-damaged mouse utricle.
Jung JY, Avenarius MR, Adamsky S, Alpert E, Feinstein E, Raphael Y.
Mol Ther. 2013 Apr;21(4):834-41. doi: 10.1038/mt.2013.18. Epub 2013 Feb 26.

ASPP1/2 regulate p53-dependent death of retinal ganglion cells through PUMA and Fas/CD95 activation in vivo.
Wilson AM, Morquette B, Abdouh M, Unsain N, Barker PA, Feinstein E, Bernier G, Di Polo A. J Neurosci. 2013 Jan 30;33(5):2205-16. doi: 10.1523/JNEUROSCI.2635-12.2013.

RTP801 is required for ceramide-induced cell-specific death in the murine lung.
Kamocki K, Van Demark M, Fisher A, Rush NI, Presson RG Jr, Hubbard W, Berdyshev EV, Adamsky S, Feinstein E, Gandjeva A, Tuder RM, Petrache I.
Am J Respir Cell Mol Biol. 2013 Jan;48(1):87-93. doi: 10.1165/rcmb.2012-0254OC. Epub 2012 Sep 28.

Neuroprotection in a novel mouse model of multiple sclerosis.
Lidster K, Jackson SJ, Ahmed Z, Munro P, Coffey P, Giovannoni G, Baker MD, Baker D.
PLoS One. 2013 Nov 4;8(11):e79188. doi: 10.1371/journal.pone.0079188. eCollection 2013.

Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.
Thompson JD, Kornbrust DJ, Foy JW, Solano EC, Schneider DJ, Feinstein E, Molitoris BA, Erlich S. Nucleic Acid Ther. 2012 Aug;22(4):255-64. doi: 10.1089/nat.2012.0371.

Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study).
Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Aitchison R, Erlich SS; DEGAS Clinical Study Group.
Invest Ophthalmol Vis Sci. 2012 Nov 15;53(12):7666-74. doi: 10.1167/iovs.12-9961.

Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.
Thompson JD, Kornbrust DJ, Foy JW, Solano EC, Schneider DJ, Feinstein E, Molitoris BA, Erlich S.
Nucleic Acid Ther. 2012 Aug;22(4):255-64. doi: 10.1089/nat.2012.0371.

Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study)
Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Aitchison R, Erlich SS; MONET Clinical Study Group.
Ophthalmology. 2012 Sep;119(9):1867-73. doi: 10.1016/j.ophtha.2012.03.043. Epub 2012 Jun 8.

Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients.
Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Khan A, Aitchison R, Erlich SS; PF-04523655 Study Group.
Eye (Lond). 2012 Aug;26(8):1099-105. doi: 10.1038/eye.2012.106. Epub 2012 May 25.

Assessing unintended hybridization-induced biological effects of oligonucleotides.
Lindow M, Vornlocher HP, Riley D, Kornbrust DJ, Burchard J, Whiteley LO, Kamens J, Thompson JD, Nochur S, Younis H, Bartz S, Parry J, Ferrari N, Henry SP, Levin AA.
Nat Biotechnol. 2012 Oct;30(10):920-3. doi: 10.1038/nbt.2376. No abstract available.

Ocular neuroprotection by siRNA targeting caspase-2.
Ahmed Z, Kalinski H, Berry M, Almasieh M, Ashush H, Slager N, Brafman A, Spivak I, Prasad N, Mett I, Shalom E, Alpert E, Di Polo A, Feinstein E, Logan A.
Cell Death Dis. 2011 Jun 16;2:e173. doi: 10.1038/cddis.2011.54.

Delayed intrathecal delivery of RhoA siRNA to the contused spinal cord inhibits allodynia, preserves white matter, and increases serotonergic fiber growth.
Otsuka S, Adamson C, Sankar V, Gibbs KM, Kane-Goldsmith N, Ayer J, Babiarz J, Kalinski H, Ashush H, Alpert E, Lahav R, Feinstein E, Grumet M.
J Neurotrauma. 2011 Jun;28(6):1063-76. doi: 10.1089/neu.2010.1568.

Intravital two-photon microscopy assessment of renal protection efficacy of siRNA for p53 in experimental rat kidney transplantation models.
Imamura R, Isaka Y, Sandoval RM, Ori A, Adamsky S, Feinstein E, Molitoris BA, Takahara S.Cell Transplant. 2010;19(12):1659-70. doi: 10.3727/096368910X516619. Epub 2010 Aug 17.

Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema.
Yoshida T, Mett I, Bhunia AK, Bowman J, Perez M, Zhang L, Gandjeva A, Zhen L, Chukwueke U, Mao T, Richter A, Brown E, Ashush H, Notkin N, Gelfand A, Thimmulappa RK, Rangasamy T, Sussan T, Cosgrove G, Mouded M, Shapiro SD, Petrache I, Biswal S, Feinstein E, Tuder RM.
Nat Med. 2010 Jul;16(7):767-73. doi: 10.1038/nm.2157. Epub 2010 May 16.

siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury.
Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E, Brafman A, Faerman A, Atkinson SJ, Thompson JD, Kalinski H, Skaliter R, Erlich S, Feinstein E.
J Am Soc Nephrol. 2009 Aug;20(8):1754-64. doi: 10.1681/ASN.2008111204. Epub 2009 May 21.

RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S.
Cancer Res. 2008 Oct 1;68(19):7975-84. doi: 10.1158/0008-5472.CAN-08-1401.

Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway.
Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E, Frolova EI, Kovriga I, Gudkov AV, Feinstein E, Chumakov PM.
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6302-7. doi: 10.1073/pnas.0802091105. Epub 2008 Apr 18.

Studies on the cholesterol-free mouse: strong activation of LXR-regulated hepatic genes when replacing cholesterol with desmosterol.
Heverin M, Meaney S, Brafman A, Shafir M, Olin M, Shafaati M, von Bahr S, Larsson L, Lövgren-Sandblom A, Diczfalusy U, Parini P, Feinstein E, Björkhem I.
Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2191-7. Epub 2007 Aug 30.

p120 catenin regulates lamellipodial dynamics and cell adhesion in cooperation with cortactin.
Boguslavsky S, Grosheva I, Landau E, Shtutman M, Cohen M, Arnold K, Feinstein E, Geiger B, Bershadsky A.
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10882-7. Epub 2007 Jun 18.

Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes
Ohyama Y, Meaney S, Heverin M, Ekström L, Brafman A, Shafir M, Andersson U, Olin M, Eggertsen G, Diczfalusy U, Feinstein E, Björkhem I.
J Biol Chem. 2006 Feb 17;281(7):3810-20. Epub 2005 Nov 30.

Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.
Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV.
Nat Chem Biol. 2006 Sep;2(9):474-9. Epub 2006 Jul 23.

p53 is a suppressor of inflammatory response in mice.
Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, Nedospasov SA, Hazen SL, Feinstein E, Gudkov AV.
FASEB J. 2005 Jun;19(8):1030-2. Epub 2005 Apr 5.

Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer.
May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E.
Oncogene. 2005 Feb 3;24(6):1011-20.

Inhibition of oxygen-induced retinopathy in RTP801-deficient mice.
Brafman A, Mett I, Shafir M, Gottlieb H, Damari G, Gozlan-Kelner S, Vishnevskia-Dai V, Skaliter R, Einat P, Faerman A, Feinstein E, Shoshani T.
Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3796-805.

Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD.
Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM.
Science. 2004 Apr 23;304(5670):596-600.

Identification and handling of artifactual gene expression profiles emerging in microarray hybridization experiments.
Brodsky L, Leontovich A, Shtutman M, Feinstein E.
Nucleic Acids Res. 2004 Mar 3;32(4):e46.

CMF608-a novel mechanical strain-induced bone-specific protein expressed in early osteochondroprogenitor cells.
Segev O, Samach A, Faerman A, Kalinski H, Beiman M, Gelfand A, Turam H, Boguslavsky S, Moshayov A, Gottlieb H, Kazanov E, Nevo Z, Robinson D, Skaliter R, Einat P, Binderman I, Feinstein E.
Bone. 2004 Feb;34(2):246-60.

Generation of viable cholesterol-free mice.
Wechsler A, Brafman A, Shafir M, Heverin M, Gottlieb H, Damari G, Gozlan-Kelner S, Spivak I, Moshkin O, Fridman E, Becker Y, Skaliter R, Einat P, Faerman A, Björkhem I, Feinstein E.
Science. 2003 Dec 19;302(5653):2087. No abstract available.

Molecular analysis of transitional cell carcinoma using cDNA microarray.
Mor O, Nativ O, Stein A, Novak L, Lehavi D, Shiboleth Y, Rozen A, Berent E, Brodsky L, Feinstein E, Rahav A, Morag K, Rothenstein D, Persi N, Mor Y, Skaliter R, Regev A.
Oncogene. 2003 Oct 23;22(48):7702-10.

The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort.
Bretsky P, Haiman CA, Gilad S, Yahalom J, Grossman A, Paglin S, Van Den Berg D, Kolonel LN, Skaliter R, Henderson BE.
Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):733-8.

The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection.
Simberg D, Weisman S, Talmon Y, Faerman A, Shoshani T, Barenholz Y.
J Biol Chem. 2003 Oct 10;278(41):39858-65. Epub 2003 Jul 17.

Nrf2 is an inhibitor of the Fas pathway as identified by Achilles’ Heel Method, a new function-based approach to gene identification in human cells.
Kotlo KU, Yehiely F, Efimova E, Harasty H, Hesabi B, Shchors K, Einat P, Rozen A, Berent E, Deiss LP.
Oncogene. 2003 Feb 13;22(6):797-806.

Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability.
Budanov AV, Shoshani T, Faerman A, Zelin E, Kamer I, Kalinski H, Gorodin S, Fishman A, Chajut A, Einat P, Skaliter R, Gudkov AV, Chumakov PM, Feinstein E.
Oncogene. 2002 Sep 5;21(39):6017-31.

Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis.
Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze’ev A.
Genes Dev. 2002 Aug 15;16(16):2058-72.

Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis.
Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, Kalinski H, Kamer I, Rozen A, Mor O, Keshet E, Leshkowitz D, Einat P, Skaliter R, Feinstein E.
Mol Cell Biol. 2002 Apr;22(7):2283-93.

Expression of prostate specific antigen (PSA) is negatively regulated by p53.
Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, Gudkov AV.
Oncogene. 2002 Jan 3;21(1):153-7.

Rare variants of ATM and risk for Hodgkin’s disease and radiation-associated breast cancers.
Offit K, Gilad S, Paglin S, Kolachana P, Roisman LC, Nafa K, Yeugelewitz V, Gonzales M, Robson M, McDermott D, Pierce HH, Kauff ND, Einat P, Jhanwar S, Satagopan JM, Oddoux C, Ellis N, Skaliter R, Yahalom J.
Clin Cancer Res. 2002 Dec;8(12):3813-9.

Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality.
Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T, Croce CM, Cimino G, Canaani E.
Oncogene. 2001 Feb 15;20(7):874-8.

Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein.
Kondratov RV, Komarov PG, Becker Y, Ewenson A, Gudkov AV.
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):14078-83. Epub 2001 Nov 13.

Different impact of p53 and p21 on the radiation response of mouse tissues.
Komarova EA, Christov K, Faerman AI, Gudkov AV.
Oncogene. 2000 Aug 3;19(33):3791-8.

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.
Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV.
Science. 1999 Sep 10;285(5434):1733-7.

Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53.
Komarova EA, Diatchenko L, Rokhlin OW, Hill JE, Wang ZJ, Krivokrysenko VI, Feinstein E, Gudkov AV.
Oncogene. 1998 Sep 3;17(9):1089-96.

Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia.
Stein I, Itin A, Einat P, Skaliter R, Grossman Z, Keshet E.
Mol Cell Biol. 1998 Jun;18(6):3112-9.